Loading clinical trials...
Loading clinical trials...
A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)
Conditions
Interventions
Glatiramer Acetate (GA) 40 mg
glatiramer acetate 20 mg
Start Date
August 1, 2006
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
October 10, 2011
NCT04047628
NCT04602390
NCT05978531
NCT04225312
NCT03536559
NCT05446285
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions